2nd National Post-SOX Forum on PHARMACEUTICAL CORPORATE GOVERNANCE

MANAGING DISCLOSURE & INTERNAL CONTROLS AND ASSESSING COMPENSATION PRACTICES & COMPLIANCE PROGRAM EFFECTIVENESS

OCTOBER 16-17, 2006  Flatotel  New York, NY

FEATURING EXCEPTIONAL FACULTY FROM: Get practical and tactical guidance from healthcare practitioners, in-house counsel, compliance officers and government enforcers on how to: AIG/National Union EARN  REEVALUATE your disclosure policy to ensure preapproval Bayer HealthCare CLE statements are addressed ETHICS  RESPOND to enhanced FDA and SEC inter-agency cooperation CREDITS Eli Lilly  ImClone Systems BALANCE competing interests as a result of new executive compensation disclosure rules Millennium Pharmaceuticals  MONITOR internal controls to protect against fraud and accounting abuse Neose Technologies  DETERMINE appropriate policies given the tension between whistleblower requirements under SOX and EU data protection laws  Schering-Plough DEVISE best implementation strategies with regard to new state reporting laws  Taro Pharmaceuticals U.S.A. DEVELOP clear policies to prevent FCPA violations  RESPOND appropriately to increased shareholder activism BRIEFING PAPER SPONSOR:  MANAGE internal investigations, including those against high-ranking officials, relative to corporate governance

SPECIAL SESSION ALERT DOCUMENTATION SPONSOR: Case Study: Life Under a Corporate Integrity Agreement Plus, a panel on Response and Remediation in Today’s Disclosure Landscape led by a former Special Assistant to the Chief Counsel of FDA and a former SEC Associate Regional Director and Co-Head of Enforcement

MEDIA PARTNER: SPECIAL ADDRESSES FROM: Assistant Regional Director Chief, Major Crimes Unit Division of Enforcement U.S. Attorney’s Office U.S. Securities & Exchange Commission Southern District of New York

Register Now • 888-224-2480 • AmericanConference.com/rxcorpgov Master the New Corporate Governance Obligations That Are Changing the Way Pharmaceutical Companies Operate

Today the pharmaceutical industry faces unique obligations and proposals in building effective corporate governance and related compliance programs. Good corporate citizenship often finds itself at odds with industry practices which — until the recent wake of corporate scandals — were considered standard. The recent collaboration between the FDA and the SEC concerning the disclosure obligations of publicly held pharmaceutical companies relative to preapproval promotion has caused further complications in the development and management of internal controls to protect against corporate fraud and accounting abuse. And pharmaceutical companies increasingly are finding themselves subject to shareholder activism on majority voting, director nominations, election processes, and executive compensation disclosures.

Add to this new multinational and multistate governance issues: tension between SOX whistleblower requirements and EU data protection laws; questions on how to incorporate FCPA controls relating to physicians; concerns relative to compliance with new state reporting obligations; and the education, management and training of employees. Other concerns related to managing internal investigations of alleged breaches and associated with responding to noncompliance or government investigations linger. All this has only served to make your quest to be vigilant in corporate housekeeping more difficult. Your risk of monetary, criminal and social consequences associated with scandal have increased.

Your ability to build effective corporate governance and related compliance programs mandates that you have the ability to comply with these unique obligations and respond appropriately to proposals. There is one place you can equip yourself with the tools needed to overcome these uncertainties. Come to American Conference Institute’s 2nd National Post SOX Forum on Pharmaceutical Corporate Governance, the conference for in-house counsel and executives in the pharmaceutical industry who deal in securities, governance and related disciplines. Our faculty of leading in-house counsel and compliance officers, expert attorneys and government enforcers will give thoughtful and targeted commentary on the most pressing corporate governance concerns particular to this industry. Topics to be covered include: • Using SOX 404 compliance to your advantage in your risk mitigation and management approaches • Assessing the impact of ASP reporting and certifications, ASP models, and active AWP cases on corporate governance • Squaring Regulation F-D and other disclosure issues with the unique confidential relationship companies have with the FDA • Complying with governance obligations through your records management policies and practices • Managing internal controls regarding the rules and regulations of FDA, Medicare, Medicaid and other federal and state healthcare programs as they apply to governance • Responding to pending proposals related to majority voting and the director nomination and election process Other highlights of this program include: • Special Focus Sessions on: - Structuring and Disclosing Executive Compensation - Designing, Implementing, and Overseeing an Appropriate Reporting Structure - What You Must Know and Implement With Respect to Codes of Ethics, Educating Management, and Training Employees - Emerging Issues in the Directors & Officers Liability Insurance Marketplace • An Enforcement Roundtable will assess trends and developments in external government investigations and enforcement actions Take this opportunity to get the information you need from leading edge legal practitioners as you network with colleagues. Delegates will also benefit from the extensive written materials prepared by the speakers especially for this conference. Register now by calling 888-224-2480, faxing your registration form to 877-927-1563 or registering online at www.americanconference.com/rxcorpgov

Register now: 888-224-2480 • fax: 877-927-1563 • AmericanConference.com/rxcorpgov MONDAY, OCTOBER 16, 2006 - determining whether disclosure is required regarding adverse actions taken (or expected to be taken) by the FDA - knowing the ramifications of failing to disclose what a 8:15 Co-Chairs’ Opening Remarks trial was designed to show and the company’s role in the drug development process Robert Hickok • Educating management on the SEC’s and FDA’s positions Partner on premarketing promotional statements Pepper Hamilton LLP • How SEC’s Release Guidance Regarding MD&A and new (Philadelphia, PA) FDA/SEC cooperation have affected scrutiny of disclosures Tanya Dobash • Identifying the FDA's obligations to comply with its Vice President & Chief Counsel, North America regulations before sharing nonpublic information with the SEC Taro Pharmaceuticals U.S.A., Inc. • Analyzing the FDA’s procedures for sharing nonpublic (Hawthorne, NY) information with the SEC

8:25 Response and Remediation in Today’s 9:35 Managing Information Systems that Disclosure Landscape: SOX 302, Impact Reporting: Best Practices on Pre-Marketing Promotional Statements, Financial Controls under SOX 404 FDA-SEC Interaction, and Beyond Robert F. Dow, JD, CPA, CMA Gregory Mayes Partner Assistant Vice President, Legal and Chief Compliance Counsel Arnall Golden Gregory LLP ImClone Systems Incorporated (Atlanta, GA) (Branchburg, NJ) Ralph Monte Coleen Klasmeier Principal Counsel KPMG LLP Sidley Austin LLP (Short Hills, NJ) (Washington, DC) • Assessing, managing, and monitoring internal (former Special Assistant to the Chief Counsel of FDA) controls to protect against fraud and accounting abuse Barry W. Rashkover • Delegating responsibility for internal controls Partner over financial reporting Sidley Austin LLP • What management’s annual evaluation and auditor (New York, NY) report must indicate (former SEC Associate Regional Director • The framework for internal controls over financial and Co-Head of Enforcement for Northeast) reporting and the use of definitions • Hiring an independent accounting firm to assist The Role of Disclosure in Today’s Environment with SOX 404 compliance • Communicating with functional heads, independent • Key SOX 404 issues for audit committees auditors, outside legal counsel and audit committees to • Analyzing how Public Company Accounting Oversight ensure all reportable events are considered for disclosure Board (PCAOB) requirements impact internal control • Adopting a disclosure policy that lays out procedures and over financial reporting contact persons for receipt of material nonpublic information • Documenting and assessing billing practices - establishing procedures for responding to third-party inquiries • Incorporating the latest on revenue recognition • Ensuring your disclosure policy is communicated and inventory treatment to all employees • Determining when automation of internal controls - training employees on the policy is worth it, and the factors that affect the decision • Ensuring your internal review team has adequate • Using SOX 404 compliance to your advantage in time to review statements for accuracy your risk mitigation and management approaches • Disclosure in the proper context to prevent investors • Addressing the overlap between disclosure controls from making erroneous conclusions and internal controls • Understanding the needs of various constituencies reviewing your disclosure 10:35 Morning Coffee Break Q

Specific Disclosure Areas Affecting the Pharmaceutical Industry 10:50 Addressing the Post-SOX Impact of • Evaluating the way in which you make premarketing Whistleblowers: Meeting Your Compliance promotional statements, and who makes the statements • Reevaluating your disclosure policy to ensure preapproval Obligations While Not Unnecessarily statements are addressed Opening Yourself Up to Suits • Monitoring preapproval promotional statements to ensure Joel Goldberg compliance with your policy Associate General Counsel and Chief Compliance Officer • Adapting to the scrutiny-level change related to Millennium Pharmaceuticals, Inc. premarketing promotional statements (Cambridge, MA) - disclosing positive results from clinical trials without disclosing how these trials relate to the company’s Holly J. Hoehner overall development program Counsel - disclosing partial results from clinical trials Hiscock & Barclay LLP - selectively disclosing FDA activity (Syracuse, NY)

Register now: 888-224-2480 • fax: 877-927-1563 • AmericanConference.com/rxcorpgov • Instilling the message of compliance in your company training Educating Management and Training Employees • Knowing employer actions that are prohibited • Educating directors and senior management • Processing employee complaints on corporate governance • Assessing and rebutting a prima facie case • Convincing the board and senior management about • The latest on whistleblower protection for those the bottom line benefits of a strong compliance and ethics who report financial fraud program before the government begins an investigation • Affording protections: What audit committee procedures • Practical and effective tips for education and training and compliance programs should require for whistleblowers programs on compliance • Lessons learned from recent pharmaceutical company • Special issues with training sales and marketing personnel whistleblower actions for life sciences companies • Determining whether employees are using whistleblower • Finding the time and money for “best in class” training status as a defense to a legitimate adverse employment action when you are faced with daily business challenges, • Determining whether — and if so how — to take legitimate including limited resources nonretaliatory action against an alleged whistleblower • The implications of failing to implement effective • Dealing with the uncertainty of whether your employee training and education programs is talking to the government • Determining appropriate policies given the tension between 12:45 Networking Luncheon whistleblower requirements under SOX and EU data protection laws • What you must know about criminal antiretaliation 2:00 Designing, Implementing, and Overseeing and SOX 1107 an Appropriate Reporting Structure James Lovett 11:40 OIG & FSG+ for Your Governance Program: Corporate Senior Vice President and General Counsel What You Must Know and Implement Covance, Inc. With Respect to Codes of Ethics, Educating (Princeton, NJ) Management, and Training Employees • Mastering the respective roles of the audit committee, officers and directors, chief legal counsel and outside Gary Budney counsel, and chief compliance officer with respect to Vice President and Compliance Officer effective compliance programs and SOX requirements Schering-Plough Corporation • Evolving practices with respect to CEO roles (Kenilworth, NJ) • Addressing the evolving role of the audit committee Tanya Dobash • Assessing the impact of Final Rule: Implementation of Vice President & Chief Counsel, North America Standards of Professional Conduct for Attorneys Taro Pharmaceuticals U.S.A., Inc. - will “reporting out” and noisy withdrawals follow (Hawthorne, NY) “reporting up”? Katayun I. Jaffari • Impact of 2003 ABA Task Force on Corporate Partner Responsibility and changes to Model Rules [1.6(b) & 1.13] Saul Ewing LLP on lawyers as key participants to governance (Philadelphia, PA) • Structuring the relationship between the compliance function and the legal function The Federal Sentencing Guidelines set forth two basic standards • Using your reporting structure in real-world situations and seven minimum requirements for an effective ethics program. Further, under the OIG Compliance Guidance for Pharmaceutical Manufacturers, one of the elements recognized MERGING SOX WITH OTHER REPORTING as fundamental to an effective compliance program includes REQUIREMENTS TO WHICH THE conducting effective education and training. This panel will PHARMACEUTICAL INDUSTRY IS BOUND ETHICS enable you not only to incorporate the “paper” aspects of the system with respect to codes of ethics, educating management, and training employees, but also will help you truly look at your 2:40 New State Reporting Laws: Devising ethics policies and training programs to evaluate whether they Best Implementation Strategies for will prevent noncompliance and ensuing penalties. Topics to be covered include: Your Governance Program Codes of Ethics Jeffrey M. Greenman Vice President, Compliance Officer • Prioritizing the matters and issues that an effective Bayer HealthCare LLC code of ethics should address (West Haven, CT) • Using an effective code of ethics to assist the board and Alan Bennett management to protect against judicial and administrative Partner actions and penalties Ropes & Gray LLP • Addressing ethical issues for publicly traded companies (Wahington, DC) and those specifically for life sciences companies • Recognizing and responding appropriately to the latest • Discussing the enactment of the latest state reporting obligations ethical dilemmas • CA, MN, WV, DC, VT, and ME: The mechanisms used • Factoring in the latest risk areas for auditing and monitoring and the latest interpretation and implementation strategies • Corporate record housekeeping with respect to expenditure, gift, and meal reporting associated with these state obligations

Register now: 888-224-2480 • fax: 877-927-1563 • AmericanConference.com/rxcorpgov • Overcoming compliance challenges with these state - Schering-Plough obligations in the pre-report activity phase - Micrus - designating individuals with responsibility - Titan Matter over reporting activities • What you must know with regard to new corporate criminal - identifying broad categories of payments/expenses liability statutes abroad resulting in increased investigations that are potentially reportable by foreign prosecutors and an increased pipeline of cases to - identifying actual payments the DOJ - collecting and compiling information • How subsidiaries also face direct risks: DPC and beyond - bases for excepting payments from reports • Applying the latest on penalties, including disgorgement • Overcoming compliance challenges and obligations of profits in the report submission phase • Addressing the trend toward deferred prosecutions, • Protecting confidential information at all phases rather than nonprosecutions • Taking corrective action if you identify potential issues • Addressing increased M&A risks • Lessons learned from state reporting obligations and • Imposing independent monitors and other oversight monitors findings thereof on an organization’s corporate • The role of management and the Audit Committee governance/compliance program in FCPA investigations • Implementing global procedures: 3:30 Afternoon Refreshment Break - ensuring each market is responsible for local implementation and enforcement - ensuring all local systems, processes, and controls 3:45 Emerging Governance Challenges are subject to periodic corporate auditing with Respect to Medicare Part D - using the bidding process to ensure compliance and Pricing Reform - appropriate record retention - training, training, and more training R. Kenneth Gordon • Robust FCPA auditing and red flags during auditing Partner • Addressing the intersection/overlap between FCPA and SOX Baker & McKenzie LLP (Dallas, TX) Special Physician Concerns • Assessing the impact of ASP reporting and certifications, • Addressing the issue that many, if not most, foreign ASP models, and active AWP cases on corporate governance physicians will be deemed foreign government officials • Evaluating the government’s increased role as a purchaser by the DOJ • Analyzing your existing PAP program activities • Dealing with advisory boards, post-marketing trials, • Knowing whether to restructure or discontinue consultant meetings and promotional events under the FCPA existing arrangements • Applying the latest interpretations of foreign officials, intent, • Establishing ongoing monitoring mechanisms jurisdiction and business nexus by the DOJ and SEC • Ensuring appropriate review of LTC or specialty contracts • The payments (hospitalities, gifts, entertainment) • Addressing Part D bidding and formularies through to physicians and relatives that may be deemed your governance program “corrupt” under the FCPA • Staying abreast of CMS “sub-regulatory” guidance • What you must know about promotional events organized • Dealing with the “spread” between the cost to your for physicians (including employees of public hospitals) direct customers and the amount paid by state and with little or no business purpose federal health programs • How to handle a lack of substantiating documentation • The then and now on payment methods, investigatory for payments for services to physicians employed by public techniques, P&Ps, designated authority, and training hospitals or reimbursed by state ministries of health • Determining whether you can pay referral fees, commissions, or consulting fees to physicians 4:30 Developing Policies and Procedures to employed by public hospitals Prevent FCPA Violations and Address Other International Compliance Challenges 5:50 Conference Adjourns Robert Hickok Partner TUESDAY, OCTOBER 17, 2006 Pepper Hamilton LLP (Philadelphia, PA) 8:10 Co-Chairs’ Opening Remarks Tanya M. Jaeger de Foras Senior Corporate Counsel, Europe & Canada Pfizer Global Pharmaceuticals, Legal Division 8:20 Structuring and Disclosing (New York, NY) Executive Compensation Jacqueline C. Wolff Arthur S. Meyers Of Counsel Partner Covington & Burling Seyfarth Shaw LLP (New York, NY) (Boston, MA) General Mark E. Bokert Partner • Lessons learned from: Davis & Gilbert LLP - Syncor International (New York, NY)

Register now: 888-224-2480 • fax: 877-927-1563 • AmericanConference.com/rxcorpgov • What you must know about the SEC’s proposed new 11:15 What to Watch for in Investor executive compensation disclosure rules, including: Relations: Regulation F-D and Beyond - a new Compensation and Discussion Analysis section - an expanded and reorganized Summary Compensation Table Jacob S. Frenkel - enhanced disclosure for equity compensation, retirement Shareholder plans, severance, and change in control arrangements Shulman, Rogers, Gandal, Pordy & Ecker, P.A. - a Director Compensation Table (Rockville, MD) • Balancing the interests of shareholders and executives Debra J. Poul with cost-effective pay packages Senior Vice President, General Counsel and Secretary - the proper use of compensation consultants Neose Technologies, Inc. - tallying total compensation (Horsham, PA) - implementing pay-for-performance initiatives - the latest on stock ownership guidelines • How the interests of large institutional investors - avoiding investor “hot buttons” differ from those of ordinary investors • What you must know about IRC 409A — the new deferred • Why there are differing interests of special concern compensation rules to the pharmaceutical industry - key requirements of IRC 409A to factor in • Best practices in navigating the changing landscape - assessing the impact on existing deferred compensation created by Regulation F-D arrangements • Assessing the impact of SEC’s latest enforcement - best practices for designing new deferred actions, including: compensation arrangements - In the Matter of FlowServe Corporation • What you must know about FAS 123r – The new - In the Matter of Siebel Systems, Inc. accounting rules for stock-based compensation - In the Matter of Schering-Plough Corporation - key features of FAS 123r to factor in - In the Matter of Raytheon Company - assessing the impact on stock plans - In the Matter of Secure Computing Corporation - assessing equity compensation trends in light of FAS 123r - Report of Investigation in the Matter of Motorola, Inc. • Squaring Regulation F-D and other disclosure issues with the unique confidential relationship companies 9:30 Responding to the Increased have with the FDA Shareholder Activism Landscape 12:15 Networking Luncheon Grace Lee Senior Counsel for Securities Law and Governance Schering-Plough Corporation 1:30 A Practical Guide to Records Management (Kenilworth, NJ) for Pharmaceutical Companies Alan L. Dye Frederick Robinson Partner Partner Hogan & Hartson LLP Fulbright & Jaworski L.L.P. (Washington, DC) (Washington, DC) Pharmaceutical companies have been the subject of a number of • Understanding the legal imperative of effective shareholder proposals in recent years, including those relating to records management drug reimportation through Canada, phasing out the use of • Defining and measuring “effectiveness” animals in product testing, and the implementation of price • Special considerations under 21 CFR Part 11 and other restraints on pharmaceutical products. In addition, there are regulatory requirements pending proposals related to majority voting and the director • Preserving records for litigation and government investigations nomination and election process. Such proposals are changing the way pharmaceutical companies operate. This session will 2:10 Afternoon Refreshment Break help you stay on top of the current corporate governance trends in the industry and respond to them appropriately. 2:25 Conducting Effective Internal Investigations 10:30 Morning Coffee Break Q and Assessing Trends and Developments in External Government Investigations 10:45 Emerging Issues in the Directors & and Enforcement Actions Officers Liability Insurance Marketplace Kay Lackey Assistant Regional Director, Division of Enforcement John Benedetto U.S. Securities & Exchange Commission President-National Accounts Management Liability (New York, NY) American International Group/National Union (New York, NY) Robin E. Abrams Vice President, Associate General Counsel • Understanding the current state of the directors & officers Purdue Pharma L.P liability insurance marketplace for pharmaceutical risks (Stamford, CT) • Incorporating the latest on capital availability, pricing, and structures of programs Lynn A. Neils • Factors pharmaceutical clients should consider when Chief, Major Crimes Unit purchasing D&O coverage U.S. Attorney’s Office, Southern District of New York • An underwriter’s perspective of the executive compensation (New York, NY) issue as it relates to the assessment and assumption of risk Register now: 888-224-2480 • fax: 877-927-1563 • AmericanConference.com/rxcorpgov Moderator: Jonathan N. Halpern WHO SHOULD ATTEND Partner Winston & Strawn LLP (New York, NY) • Practical and strategic issues to weigh as you manage internal • For the Pharmaceutical Industry: investigations, including against high ranking officials, relative to pharmaceutical corporate governance, including - In-house counsel - the impact of industry and applicable guidelines - document collection, review, and retention challenges - Compliance officers - interviewing witnesses - what the government expects from your investigation - overcoming the latest attorney-client privilege • Senior Executives with Responsibilities in and conflict of interest challenges - whistleblower, SOX, and FCPA protocols Corporate Governance, FDA-SEC Referrals, - privacy concerns • What you must know about voluntary reporting Regulatory Affairs, SOX, Finance and Auditing to the government - how to proceed when you find a problem • Attorneys Practicing in Food, Drug and Healthcare - making a credible presentation of internal investigation results to the government without inviting further scrutiny Regulatory Law, Securities and Litigation and - weighing the affects of voluntary disclosure to the government on the plaintiffs’ bar Enforcement, and White-Collar Crime • The matters that confront any entity or person facing an external government investigation or enforcement action - once the investigation begins, how to react and conduct yourself - what you must know about the Thompson CONTINUING LEGAL EDUCATION CREDITS Memorandum and diversion/deferred prosecution

3:35 Case Study: Life Under a Accreditation will be sought in those jurisdictions EARN Corporate Integrity Agreement requested by registrants which have continuing legal CLE ETHICS Lori Queisser education requirements. To request credit, please check CREDITS Vice President and Chief Compliance Officer the appropriate box on the Registration Form. (Indianapolis, IN) This course has been approved in accordance with the requirements Larry A. Mackey of the New York State Continuing Legal Education Board in the Partner amount of 16.5 hours, 1.0 of which will apply to legal ethics. Barnes & Thornburg LLP (Indianapolis, IN) ACI certifies that this activity has been approved for CLE credit • A present-day perspective on what it’s like to be the subject by the State Bar of California in the amount of 14.0 hours, of a consent decree that incorporates an extensive CIA 1.0 of which will apply to legal ethics. • Incorporating the lessons learned from past CIAs into your corporate governance/compliance program • Understanding the true dynamic of CIAs and consent decrees, and the relationship formed with the government as a result of them - what to expect from the DOJ SPONSORSHIP OPPORTUNITIES • Post-decree CIA management: Why it’s one thing to enter it, and quite another thing to abide by it • Post-decree experience: What to tell the prosecutor ACI works closely with each sponsor to create a distinctive package tailored to on company developments individual marketing and business development objectives. Our objective • The latest on enforceability of consent decrees and breach of consent decrees with every sponsor is to foster a rewarding and long-term partnership • What you must know about unintentional breaches through the delivery of a wide variety of sponsorship benefits and thought leadership opportunities. For more information, please contact: 4:30 Conference Ends Benjamin Greenzweig Director of Business Development, U.S. (212) 352-3220 ext. 238 or [email protected]

© American Conference Institute, 2006 Register now: 888-224-2480 • fax: 877-927-1563 • AmericanConference.com/rxcorpgov 2nd National Post-SOX Forum on SPECIAL SESSION ALERT Case Study: Life Under a Corporate Integrity Agreement

PHARMACEUTICAL Plus, a panel on Response and Remediation in Today’s Disclosure Landscape led by CORPORATE GOVERNANCE a former Special Assistant to the Chief Counsel of FDA MANAGING DISCLOSURE & INTERNAL CONTROLS AND and a former SEC Associate ASSESSING COMPENSATION PRACTICES & COMPLIANCE PROGRAM EFFECTIVENESS Regional Director and Co-Head of Enforcement OCTOBER 16-17, 2006  Flatotel  New York, NY

REGISTRATION FORM 5 Easy Ways to Register

PRIORITY SERVICE CODE:  MAIL American Conference Institute 41 West 25th Street New York, NY 10010 ℡ PHONE 888-224-2480  FAX 877-927-1563 ONLINE  AmericanConference.com/rxcorpgov EMAIL  CustomerCare ATTENTION MAILROOM: If undeliverable to addressee, @AmericanConference.com please forward to: ASSISTANT GENERAL COUNSEL COMPLIANCE OFFICER

CONFERENCE CODE: 613L07-NYC Hotel Information o YES! Please register the following delegate(s) for the PHARMACEUTICAL VENUE: Flatotel CORPORATE GOVERNANCE ADDRESS: 135 West 52nd Street NAME ______POSITION ______New York, NY 10019 A limited number of rooms are available at a discounted rate. To make your hotel reservation APPROVING MANAGER ______POSITION ______please visit www.globalexec.com/aci. If you need assistance please call Global Executive on 800-516- ORGANIZATION ______4265 or email [email protected]. The hotel will not be able to make or change your reservation directly. ADDRESS ______Registration Fee The fee includes the conference, all program materials, CITY ______STATE ______ZIP CODE ______continental breakfasts, lunches and refreshments. Cancellation and Refund Policy TELEPHONE ______FAX ______Substitution of participants is permissible without prior notification. If you are unable to find a substitute, please notify American Conference Institute (ACI) in writing EMAIL ______TYPE OF BUSINESS ______up to 10 days prior to the conference date and a credit voucher will be issued to you for the full amount paid, I wish to receive CLE Credits in ______(state) redeemable against any other ACI conference. If you prefer, you may request a refund of fees paid less a 15% service charge. No credits or refunds will be given FEE PER DELEGATE # for cancellations received after 10 days prior to the ❏ Conference $1895 ❏ Early Bird Conference Price $1695 conference date. ACI reserves the right to cancel any ❏ conference it deems necessary and will, in such event, I cannot attend but would like information *Save $200 when you register and make a full refund of any registration fee, but will not be regarding conference publications pay by August 1, 2006 SAVE responsible for airfare, hotel or other costs incurred by registrants. No liability is assumed by ACI for changes in ❏ Please send me information about $200 * program date, content, speakers or venue. related conferences Incorrect Mailing Information PAYMENT If you would like us to change any of your details please fax the label on this brochure to our Please charge my ❏ VISA ❏ MasterCard ❏ AMEX ❏ Please invoice me Database Administrator at 1-877-927-1563, or email [email protected]. Number ______Exp. Date ______CONFERENCE PUBLICATIONS Signature ______To reserve your copy or to receive a catalog (for credit card authorization and opt-in marketing) of ACI titles go to www.aciresources.com ❏ I have enclosed my check for $______made payable to or call 1-888-224-2480. American Conference Institute (T.I.N.—98-0116207) SPECIAL DISCOUNT We offer special pricing for groups and government PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE employees. Please email or call for details.